Orexin A is a tiny protein that acts like your brain's master wake-up alarm system. Think of it as the conductor of an orchestra, but instead of coordinating musicians, it's keeping you alert, awake, and energized throughout the day. People are interested in this peptide because when your brain doesn't make enough of it, you develop narcolepsy – that condition where people suddenly fall asleep at inappropriate times. Researchers are exploring orexin A as a potential treatment to help people stay awake when they should be alert.
Here's how it works in your body: your brain has a small region called the hypothalamus that produces orexin A, and from there it travels to wake-promoting areas throughout your brain like a wake-up message being broadcast to different radio stations. Each "station" handles a different brain chemical – one manages your norepinephrine, another your serotonin, and so on. When orexin A hits these areas, it's like flipping multiple light switches at once, activating all the systems that keep you conscious and alert. Your brain operates like a flip-flop switch – you're either awake or asleep, not stuck in between – and orexin A is what keeps that switch firmly in the "awake" position when you need to be functioning.
Dosage Information
Typical Dose
Research compound — no established human therapeutic dosing
Frequency
N/A for therapeutic use
Administration
Intranasal (research) or intracerebroventricular (animal studies)
Half-Life
20–30 minutes
Notes
Orexin replacement for narcolepsy is in clinical trials. Intranasal delivery is being investigated as a non-invasive route to restore orexin signaling in narcolepsy patients.
Why this matters
Rapidly degraded; intranasal route used in research for CNS delivery.
Where does Orexin A sit?
See how this peptide compares across all 150 peptides in our database.
Evidence Score
0.71
Compound Data
Molecular Formula
C152H243N47O44S4
Molecular Weight
3561.10 g/mol
IUPAC Name
(4S)-5-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[[(2S)-1-[[2-[[(2S)-4-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[[(2S,3S)-1-[[(2S)-1-[[(2S,3R)-1-[[(2S)-1-amino-4-methyl-1-oxopentan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-2-oxoethyl]amino]-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(1R,4S,7S,10S,13S,16R,21R,24S,31R)-7-(4-aminobutyl)-10-(3-amino-3-oxopropyl)-13-(3-carbamimidamidopropyl)-31-[[(2S)-3-carboxy-2-[[(2S)-1-[(2S)-4-methyl-2-[[(2S)-1-[(2S)-5-oxopyrrolidine-2-carbonyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]propanoyl]amino]-4-[(1R)-1-hydroxyethyl]-24-(hydroxymethyl)-3,6,9,12,15,23,26,32-octaoxo-18,19,28,29-tetrathia-2,5,8,11,14,22,25,33-octazabicyclo[14.10.7]tritriacontane-21-carbonyl]amino]-5-carbamimidamidopentanoyl]amino]-4-methylpentanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-5-oxopentanoic acid
PubChem CID
56842143Potential Side Effects
Orexin A discussions
Quick Facts
- Administration
- Intranasal (research) or intracerebroventricular (animal studies)
- Typical Dose
- Research compound — no established human therapeutic dosing
- Frequency
- N/A for therapeutic use
- References
- 0 curated + 46 from PubMed
- Clinical Trials
- 47 registered
- Evidence Score
- 0.7 / 100
Frequently Asked Questions about Orexin A
What is Orexin A?
Orexin A (Hypocretin-1) is a 33-amino-acid neuropeptide produced exclusively by neurons in the lateral hypothalamus that plays a master regulatory role in wakefulness arousal feeding behavior and reward processing. Loss of orexin neurons is the primary cause of narcolepsy with cataplexy — one of the best-characterized neurological sleep disorders. Orexin receptor antagonists (suvorexant lemborexant) are FDA-approved sleep medications demonstrating the clinical significance of this system. Orexin replacement therapy is under active investigation for narcolepsy and other hypersomnia conditions and represents a frontier in sleep medicine.
How does Orexin A work?
Orexin A acts through two G-protein-coupled receptors OX1R and OX2R distributed throughout wake-promoting brain regions including the locus coeruleus (norepinephrine) dorsal raphe (serotonin) tuberomammillary nucleus (histamine) and ventral tegmental area (dopamine). By activating these monoaminergic wake-promoting systems Orexin A stabilizes the arousal state and prevents inappropriate transitions into sleep. The orexin system acts as a flip-flop switch that maintains stable wakefulness or sleep states by mutually inhibiting competing circuits. Orexin also regulates appetite and metabolism through effects on the hypothalamic feeding centers and modulates the reward system making it relevant to addiction and compulsive behavior research. Intranasal administration can deliver orexin peptides to the brain bypassing the blood-brain barrier through olfactory and trigeminal pathways.
What is the recommended dosage for Orexin A?
The typical dose is Research compound — no established human therapeutic dosing. N/A for therapeutic use. Administration: Intranasal (research) or intracerebroventricular (animal studies). Orexin replacement for narcolepsy is in clinical trials. Intranasal delivery is being investigated as a non-invasive route to restore orexin signaling in narcolepsy patients.
What are the side effects of Orexin A?
Research compound — limited human safety data. Potential for wakefulness-promoting effects at inappropriate times. Blood pressure effects through noradrenergic activation
Questions reflect common community inquiries. This is not medical advice.